Clinical trial IJB_1841
AB04030 : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment.
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AB Science |
| EudraCT Identifier | 2008-00097-340 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT00812240 |
| Inclusion criteria | c-Kit positive tumor or PDGFR positive |
| Last update |